Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a-Induced Depression in Hepatitis C: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

The article discusses a randomized, placebo-controlled clinical trial which examined the effectiveness and safety of the escitalopram antidepressant in preventing depression in hepatitis C patients induced by interferon alfa-2a. The results showed that major depression rates were low. The rates also did not differ between the groups receiving escitalopram and placebo.